Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

pharma
Starting a New Lab
Starting a New Lab
The Scientist Creative Services Team | Aug 6, 2020
Advice for new principal investigators starting their first research laboratories!
US Selects Two COVID-19 Vaccine Candidates for Huge Investments
US Selects Two COVID-19 Vaccine Candidates for Huge Investments
Amy Schleunes | Apr 1, 2020
The government is assisting Johnson & Johnson and Moderna with expediting clinical testing while at the same time prepping for large-scale manufacturing.
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
How K2 and Other Synthetic Cannabinoids Got Their Start in the Lab
How K2 and Other Synthetic Cannabinoids Got Their Start in the Lab
Ashley Yeager | Nov 27, 2018
Originally intended for basic neuroscience research, the drugs were ultimately hijacked for illicit recreational use.
Serum Survey Reveals Protein Patterns of Ill Health
Serum Survey Reveals Protein Patterns of Ill Health
Ruth Williams | Aug 2, 2018
Analyses of blood from thousands of people show distinct protein profiles are linked to complex diseases of aging.
FDA Approves First Marijuana-Derived Drug
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.